Clinical Trial Update: To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating belinostat or pralatrexate in combination with CHOP versus CHOP alone for peripheral T cell lymphoma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Belinostat (belinostat)
• Pralatrexate (pralatrexate)

Snippet

Sponsor: Acrotech Biopharma Inc. | Conditions: Peripheral T Cell Lymphoma | Phase 3 | Status: RECRUITING